top of page
Poverty and isolation are associated with worse pulmonary hypertension outcomes
A 2024 study looked at the association between socioeconomic disadvantage and pulmonary hypertension. In one New York hospital system,...
PHA Canada
3 days ago1 min read
1 view
0 comments
Some PH patients with interstitial lung disease may benefit from oral PAH drugs
Medications for pulmonary arterial hypertension (PAH) are not approved for use in patients with pulmonary hypertension due to...
PHA Canada
Apr 141 min read
11 views
1 comment
ZENITH results published: sotatercept is effective for high-risk PAH patients
The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...
PHA Canada
Apr 81 min read
10 views
0 comments
Main pulmonary artery diameter predicts risk in PAH patients
Researchers wanted to know whether an enlarged pulmonary artery could independently predict risk in pulmonary arterial hypertension (in...
PHA Canada
Mar 311 min read
6 views
0 comments
Plain-language summary available for the TORREY seralutinib study
Seralutinib is a molecule that blocks inflammation, cell proliferation, and scarring responsible for pulmonary arterial hypertension. The...
PHA Canada
Mar 171 min read
3 views
PAH patients who skip treatment don't do as well as patients who adhere to their treatment plan
In a study of data from the Pulmonary Hypertension Association Registry in the US, researchers looked at who was more likely to skip...
PHA Canada
Mar 31 min read
6 views
Newly diagnosed PAH patients on triple therapy have fewer hospitalizations vs. double therapy
A study looked at about 3000 pulmonary arterial hypertension patients and found that people who added selexipag to double therapy (an...
PHA Canada
Feb 181 min read
14 views
HYPERION sotatercept study has positive results, stops early
The HYPERION study examined whether adding sotatercept to other therapies for recently diagnosed patients with pulmonary arterial...
PHA Canada
Feb 101 min read
16 views
0 comments
Treprostinil benefits PAH patients with cardiovascular issues
Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new...
PHA Canada
Feb 41 min read
3 views
0 comments
Sotatercept safe and effective across cardiac index groups
Cardiac index (CI) assesses the output of someone's heart based on their size. It measures heart function relative to the person's size...
PHA Canada
Dec 18, 20241 min read
23 views
0 comments
ZENITH study shows sotatercept is effective for PAH patients at high risk of mortality
The ZENITH study examined whether adding sotatercept to people's ongoing therapies reduced the risk of death, lung transplantation, or...
PHA Canada
Nov 26, 20241 min read
33 views
0 comments
Update: Canadian Drug Agency Funding Success for Pulmonary Hypertension Research
Great news for the Pulmonary Hypertension (PH) community! Through the Canadian Drug Agency's (CDA) funding initiative for rare diseases,...
PHA Canada
Oct 24, 20241 min read
23 views
0 comments
Rural and urban PH patients receive equivalent care
As most PH clinics are in large cities, PH patients living in rural or remote areas and who must travel long distances to their clinic...
PHA Canada
Oct 24, 20241 min read
11 views
0 comments
Sotatercept is now listed on Health Canada's website
We are pleased to announce that sotatercept, a new drug for patients diagnosed with pulmonary arterial hypertension (PAH), is now listed...
PHA Canada
May 13, 20241 min read
132 views
0 comments


Dr. Jason Weatherald Discusses the Burden of PAH on the PHaware Podcast
Tune in to the latest episode of the PHaware podcast, where Dr. Jason Weatherald, a pulmonologist at the University of Alberta, delves...
PHA Canada
May 5, 20241 min read
30 views
0 comments
The FDA has granted approval for the medication sotatercept
The US Food and Drug Administration (FDA) has granted approval for the medication sotatercept, a significant milestone in the treatment...
PHA Canada
Mar 26, 20241 min read
16 views
0 comments
The evolving landscape of pulmonary arterial hypertension clinical trials
In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance...
PHA Canada
Nov 26, 20221 min read
12 views
0 comments
Medications for the treatment of pulmonary arterial hypertension
PHA Canada's very own Dr. Sanjay Metha, Dr. Lisa Mielniczuk, and others have published a study in the European Respiratory Review. Read...
PHA Canada
Aug 10, 20221 min read
10 views
0 comments
Advances in Pulmonary Hypertension: Quality of Life
About Advances in Pulmonary Hypertension magazine: Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension...
PHA Canada
Jul 10, 20221 min read
6 views
0 comments
Social determinants of health in pulmonary arterial hypertension patients in the United States: Clinician perspective and health policy implications
Clinicians at 17 US pulmonary hypertension centres were interviewed about their understanding of social determinants of health in...
PHA Canada
Jul 8, 20221 min read
5 views
0 comments
bottom of page